Japan Iressa side-effect ruling favours AstraZeneca
This article was originally published in Scrip
Executive Summary
The Tokyo High Court in Japan has overturned a lower court ruling in a case relating to side-effects attributed to AstraZeneca's lung cancer drug Iressa (gefitinib), finding both the government and the firm's local subsidiary not liable for damages.